Antitumor activity of interleukin 12 in preclinical models M. J. BrundaLeopoldo LuistroAlicia V. Palleroni REVIEW Pages: S16 - S21
Application of interleukin 12 to antitumor cytokine and gene therapy T. NishimuraKazuhito WatanabeSonoko Habu ORIGINAL ARTICLE Pages: S27 - S34
In vitro model of toxin therapy targeted against murine myeloid leukemia cells A. TojoYasuo OshimaShigetaka Asano ORIGINAL ARTICLE Pages: S37 - S39
Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions Kunio MatsumotoKazuhiko DateT. Nakamura REVIEW Pages: S42 - S47
Role of glycoprotein 130 and c-Kit signaling in proliferation and differentiation of human hematopoietic progenitor cells T. NakahataXingwei SuiKohichiro Tsuji ORIGINAL ARTICLE Pages: S64 - S68
Biology and clinical potential of stem-cell factor J. GlaspyMark W. DavisIan McNiece ORIGINAL ARTICLE Pages: S53 - S57
Cloning of thrombopoietin and its therapeutic potential Hiroshi Miyazaki ORIGINAL ARTICLE Pages: S74 - S77
Is interleukin 3 active in anticancer drug-induced thrombocytopenia? Adrian C. Newland REVIEW Pages: S83 - S88
Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy Michael S. Gordon ORIGINAL ARTICLE Pages: S96 - S98
Granulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogeneic transplantation M. HaradaTakanori Teshimafor the Fukuoka Bone Marrow Transplantation Group ORIGINAL ARTICLE Pages: S115 - S119
European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: the example of breast cancer Eric C. AntoineD. Khayat REVIEW Pages: S103 - S109
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes N. SaijoKazuto NishioYasutsuna Sasaki REVIEW Pages: S11 - S15
Antitumor and antimetastatic effects of interleukin 12 H. FujiwaraToshiyuki Hamaoka ORIGINAL ARTICLE Pages: S22 - S26
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin’s lymphoma Tiziano BarbuiSergio CortelazzoA. Rossi ORIGINAL ARTICLE Pages: S110 - S114
Immunoconjugates and immunotoxins for therapy of solid tumors I. HellströmPamela TrailKarl Erik Hellström ORIGINAL ARTICLE Pages: S35 - S36
Costimulation of T-cell-mediated tumor immunity Karl Erik HellströmLieping ChenI. Hellström ORIGINAL ARTICLE Pages: S40 - S41
Differential effects of c-fms and c-kit ligands on the lineage development of the lymphohematopoietic cell line EML C1 Schickwann Tsai ORIGINAL ARTICLE Pages: S58 - S63
Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines Naoko KajimuraHideaki IsekiK. Yamaguchi ORIGINAL ARTICLE Pages: S48 - S52
Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential Thalia Papayannopoulou REVIEW Pages: S69 - S73
Angiogenesis as a new target for cancer treatment M. OnoHiroto IzumiMichihiko Kuwano ORIGINAL ARTICLE Pages: S78 - S82
Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients S. KudohToshiyuki Sawafor the SDZ ILE 964 (IL-3) Study Group ORIGINAL ARTICLE Pages: S89 - S95
Effect of interleukin 11 on normal and pathological thrombopoiesis M. TeramuraShoko KobayashiHideaki Mizoguchi ORIGINAL ARTICLE Pages: S99 - S102
New promising anticancer agents in development: what comes next? Jaap Verweij ORIGINAL ARTICLE Pages: S3 - S10